Non-invasive optical imaging allows scientists to visualize, track and quantify biological processes at the molecular level in living animals with high throughput and relatively low cost.
Caliper can provide commercial and academic customers with a selection of in vivo offerings including imaging systems, reagents, applications, proprietary methods and services that improve drug discovery and development efforts.
"This multi-year agreement further validates the importance and relevance of Caliper's optical imaging technology and intellectual property," said Kevin Hrusovsky, chief executive officer, Caliper Life Sciences.
"More than 70% of major pharmaceutical companies, and 60% of major biotech companies, now hold a license to the Caliper Optical Imaging Patent Suite, and smaller biotechs are following suit in increasing numbers."
Hrusovsky added, "Our recent notification of allowance of patent claims for conjugate fluorescence imaging methods from the U.S. Patent and Trademark Office has significantly increased the value of Caliper's intellectual property estate and complements Caliper's aggressive investment in conjugate probe development."